Fundamentally, oil bodies are discrete storage organelles found in oilseeds, comprising a hydrophobic triacylglycerol core surrounded by a half-unit phospholipid membrane and an outer shell of specialized proteins known as oleosins. Oil bodies possess a number of attributes that were exploited by SemBioSys Genetics to isolate highly enriched fractions of oil bodies through liquid-liquid phase separation for a number of commercial applications. The current chapter provides a general guide for the isolation of oil bodies from Arabidopsis and/or safflower seed, from which protocols can be refined for different oilseed sources. For SemBioSys Genetic's recombinant technology, therapeutic proteins were covalently attached to oleosins or fused in-frame with ligands which bound oil bodies, facilitating their recovery to high levels of purity during "upstream processing" of transformed seed. Core to this technology was oil body isolation consisting of simple manipulation including homogenization of seeds to free the oil bodies, followed by the removal of insoluble fractions, and phase separation to recover the oil bodies. During oil body enrichment (an increase in oil body content concomitant with removal of impurities), a number of options and tips are provided to aid researchers in the manipulation and monitoring of these robust organelles.

2012-12-01·Transgenic research4区 · 生物学

Purification of the therapeutic antibody trastuzumab from genetically modified plants using safflower Protein A-oleosin oilbody technology

4区 · 生物学

Article

作者: John Teat ; Haifeng Wang ; Michael D. McLean ; Joseph Boothe ; Rongji Chen ; Steve Zaplachinski ; Kor-Zheng Mah ; J. Christopher Hall ; Deqiang Yu

Production of therapeutic monoclonal antibodies using genetically modified plants may provide low cost, high scalability and product safety; however, antibody purification from plants presents a challenge due to the large quantities of biomass that need to be processed. Protein A column chromatography is widely used in the pharmaceutical industry for antibody purification, but its application is limited by cost, scalability and column fouling problems when purifying plant-derived antibodies. Protein A-oleosin oilbodies (Protein A-OB), expressed in transgenic safflower seeds, are relatively inexpensive to produce and provide a new approach for the capture of monoclonal antibodies from plants. When Protein A-OB is mixed with crude extracts from plants engineered to express therapeutic antibodies, the Protein A-OB captures the antibody in the oilbody phase while impurities remain in the aqueous phase. This is followed by repeated partitioning of oilbody phase against an aqueous phase via centrifugation to remove impurities before purified antibody is eluted from the oilbodies. We have developed this purification process to recover trastuzumab, an anti-HER2 monoclonal antibody used for therapy against specific breast-cancers that over express HER2 (human epidermal growth factor receptor 2), from transiently infected Nicotiana benthamiana. Protein A-OB overcomes the fouling problem associated with traditional Protein A chromatography, allowing for the development of an inexpensive, scalable and novel high-resolution method for the capture of antibodies based on simple mixing and phase separation.

2012-04-01·Transgenic research4区 · 生物学

High level accumulation of gamma linolenic acid (C18:3Δ6.9,12 cis) in transgenic safflower (Carthamus tinctorius) seeds

4区 · 生物学

Article

作者: Catherine Reed ; Maurice M. Moloney ; Joseph G. Boothe ; Cory L. Nykiforuk ; Gunamani S. Oinam ; Christine Shewmaker ; Steve Zaplachinski ; Indra Harry ; Olga P. Yurchenko ; Mei Zhang ; Ana Fidantsef

Gamma linolenic acid (GLA; C18:3Δ6,9,12 cis), also known as γ-Linolenic acid, is an important essential fatty acid precursor for the synthesis of very long chain polyunsaturated fatty acids and important pathways involved in human health. GLA is synthesized from linoleic acid (LA; C18:2Δ9,12 cis) by endoplasmic reticulum associated Δ6-desaturase activity. Currently sources of GLA are limited to a small number of plant species with poor agronomic properties, and therefore an economical and abundant commercial source of GLA in an existing crop is highly desirable. To this end, the seed oil of a high LA cultivated species of safflower (Carthamus tinctorius) was modified by transformation with Δ6-desaturase from Saprolegnia diclina resulting in levels exceeding 70% (v/v) of GLA. Levels around 50% (v/v) of GLA in seed oil was achieved when Δ12-/Δ6-desaturases from Mortierella alpina was over-expressed in safflower cultivars with either a high LA or high oleic (OA; C18:1Δ9 cis) background. The differences in the overall levels of GLA suggest the accumulation of the novel fatty acid was not limited by a lack of incorporation into the triacylgylcerol backbone (>66% GLA achieved), or correlated with gene dosage (GLA levels independent of gene copy number), but rather reflected the differences in Δ6-desaturase activity from the two sources. To date, these represent the highest accumulation levels of a newly introduced fatty acid in a transgenic crop. Events from these studies have been propagated and recently received FDA approval for commercialization as Sonova™400.

项与 SemBioSys Genetics, Inc. 相关的新闻（医药）

2006-03-21

·BioSpace

SemBioSys Genetics Inc. And Lonza Inc. Announce Expansion Of DermaSphere(R) Oleosome Technology Into New Cosmetic Applications

CALGARY, March 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a broad pipeline of protein-based pharmaceutical product candidates and non-pharmaceutical products, today announced the publication of new data on the DermaSphere(R) Oleosome Technology by the Company's licensee Lonza Inc. in the leading technology-focused personal care industry trade journal, Cosmetics & Toiletries. The article, entitled "Oleosomes: Natural, Self-emulsifying Systems", which appeared in the January 2006 edition of the journal, discusses for the first time recent research completed by Lonza on the utility of DermaSphere(R) oleosomes as a controlled-release carrier for active ingredients in personal care formulations. "These new results from Lonza independently validate the functionality of our DermaSphere(R) Oleosome Technology as both a self-emulsifying system as well as a carrier and potential delivery mechanism in cosmetic formulations," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "With Lonza expanding the application development of DermaSphere(R) oleosomes to include these additional benefits, it has increased the market opportunity to SemBioSys for this product, especially considering the marketing and distribution support that an industry leader like Lonza can offer." The article summarizes the unique combination of self-emulsification, anti-oxidation, occlusivity and emolliency benefits of oleosomes as an ingredient system. The article also provides new information describing the flexibility of oleosomes to be loaded with a wide array of oil-soluble materials, enabling its use as a carrier and delivery system for fragrances, vitamins or UV chromophores. The article reports on the remarkable stability of "loaded" oleosomes and provides evidence for controlled release of fragrances in double-blind panel testing. The article concludes that the DermaSphere(R) Oleosome Technology constitutes a true multifunctional ingredient system, providing broad utility for personal care applications. "We are constantly researching and finding new applications for this unique technology," said Carl Cappabianca, Vice President of Global Personal Care Marketing at Lonza. "More formulator benefits are around the corner as we continue our development work with DermaSphere(R) technology." Lonza used the DermaSphere(R) Oleosome Technology developed by SemBioSys to launch its Natrulon(R) OSF in late 2004. Natrulon(R) OSF, the initial product in the line which is comprised of safflower oleosomes, is distributed and supported globally by Lonza. Various upcoming technical conferences and presentations at trade shows, as well as revised advertisements and literature, will further highlight the additional DermaSphere(R) oleosome developments Lonza has discovered. The full article can be viewed by visiting Cosmetics & Toiletries' website at; . About DermaSphere(R) Oleosome Technology The DermaSphere(R) Oleosome Technology was developed by SemBioSys Genetics Inc. Lonza and SemBioSys joined forces in May of 2004 with the execution of a licensing agreement for exclusive global rights to the technology for use in personal care applications. The DermaSphere(R) Oleosome Technology is based on a natural oil-in-water emulsion derived from plant oilseeds. The emulsion is comprised of naturally occurring oil droplets called oleosomes, in which the oil is surrounded by a shell of phospholipids and unique proteins called oleosin. The oleosome core provides emolliency, occlusivity and anti-oxidant effects, and the outer shell provides emulsifying properties. An oleosome emulsion can be used as the entire non-active portion of the oil phase of a typical cosmetic formulation. With this technology cosmetic formulations can be prepared under "cold process" conditions, enabling significant savings in time, energy and inventory management. These unique attributes of the DermaSphere(R) oleosomes allow the technology to be used in a wide range of applications including moisturizing creams, sunscreens, ointments, lotions, eye-care products as well as many others. About SemBioSys Genetics Inc. ( ) Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and non-pharmaceutical products based on its plant genetic engineering skills and proprietary oilbody-oleosin technology platform - the Stratosome(TM) Biologics System. Its two lead pharmaceutical product candidates are insulin and a developmental cardiovascular drug called Apo AI. It also has a series of non-pharmaceutical products addressing animal health, nutritional oils and human topical markets. SemBioSys currently has five major funded partnership agreements including agreements with Martek Biosciences Corporation, Lonza Inc. and Arcadia Biosciences, Inc. About Lonza Inc. ( ) Lonza, a chemical and biotechnology company driven by the life sciences, generated sales of CHF 2.52 billion in 2005. Headquartered in Switzerland, Lonza operates 22 production and R&D sites around the world. Its 6300 employees are passionately committed to delivering sustainable value to their customers. Lonza is one of the leading custom manufacturers of chemical intermediates, active ingredients and biopharmaceuticals for the pharmaceutical and agrochemical industries. On the basis of organic chemical, oleochemical and biotechnology platforms, Lonza creates value-added solutions for the nutrition, hygiene & personal care, wood & water treatment and industrial specialty markets. Lonza also offers polymer intermediates, resins and compounds. Lonza is listed on the SWX Swiss Exchange. In the personal care industry, Lonza is one of the world's leading specialty chemical companies with substantial global resources in research and development, technical and applications service and broadly based manufacturing capability. Lonza has an on-going commitment to developing technology and solutions to the personal care industry in a variety of areas including world-leading positions in preservatives and specialty active compounds. Natrulon is a registered trademark of Lonza Inc. DermaSphere and Stratosome are trademarks of SemBioSys Genetics Inc. Except for historical information, this press release may contain forward-looking statements, which are based on the Company's beliefs and assumptions based on information available at the time the assumption was made. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. SemBioSys Genetics Inc. CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:bauma@sembiosys.com, Internet: Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: rmarshall@equicomgroup.com; Lonza Inc., Mr. CarlCappabianca, Vice President, Global Personal, Care Marketing, Phone: (201)316-9305, Fax: (201) 785-1364, E-mail: carl.cappabianca@lonza.com,Internet: Lonza Inc., Ms. Christine Casper, CommunicationsManager, Phone: (201) 316-9236, Fax: (201) 785-1364, E-mail:christine.casper@lonza.com, Internet:

100 项与 SemBioSys Genetics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 SemBioSys Genetics, Inc. 相关的转化医学

登录后查看更多信息